Coronini-Cronberg Sophie, Heffernan Catherine, Robinson Michael
Imperial College Healthcare NHS Trust, The Bays, South Wharf Road, St Mary's Hospital , London W2 1NY , UK.
JRSM Short Rep. 2011 Oct;2(10):78. doi: 10.1258/shorts.2011.011089. Epub 2011 Oct 14.
To review the effectiveness of smoking cessation interventions offered to chronic obstructive pulmonary disease (COPD) patients, and identify barriers to quitting experienced by them, so that a more effective service can be developed for this group.
A rapid systematic literature review comprising computerized searches of electronic databases, hand searches and snowballing were used to identify both published and grey literature.
A review of studies undertaken in north-western Europe (defined as: United Kingdom, Ireland, France, Germany, Benelux and Nordic countries).
COPD patients participating in studies looking at the effectiveness of smoking cessation interventions in this patient group, or exploring the barriers to quitting experienced by these patients.
Quantitative and qualitative papers were selected according to pre-specified inclusion and exclusion criteria, critically appraised, and quantitative papers scored against the NICE Levels of Evidence standardized hierarchy.
Percentages of successful quitters and length of quit, assessed by self-report or biochemical analysis. Among qualitative studies, identified barriers to smoking cessation had to be explored.
Three qualitative and 13 quantitative papers were finally selected. Effective interventions and barriers to smoking cessation were identified. Pharmacological support with Buproprion combined with counselling was significantly more efficacious in achieving prolonged abstinence than a placebo by 18.9% (95% CI 3.6-26.4%). Annual spirometry with a brief smoking cessation intervention, followed by a personal letter from a doctor, had a significantly higher ≥1 year abstinence rate at three years among COPD patient smokers, compared to smokers with normal lung function (P < 0.001; z = 3.93). Identified barriers to cessation included: patient misinformation, levels of motivation, health beliefs, and poor communication with health professionals.
Despite the public health significance of COPD, there is a lack of high-quality evidence showing which smoking cessation support methods work for these patients. This review describes three effective interventions, as well as predictors of quitting success that service providers could use to improve quit rates in this group. Areas that would benefit from urgent further research are also identified.
回顾为慢性阻塞性肺疾病(COPD)患者提供的戒烟干预措施的有效性,并确定他们在戒烟过程中遇到的障碍,以便为该群体开发更有效的服务。
采用快速系统文献综述,通过计算机检索电子数据库、手工检索和滚雪球法来识别已发表文献和灰色文献。
对在欧洲西北部(定义为:英国、爱尔兰、法国、德国、比荷卢经济联盟和北欧国家)开展的研究进行综述。
参与研究戒烟干预措施对该患者群体有效性或探讨这些患者戒烟障碍的COPD患者。
根据预先指定的纳入和排除标准选择定量和定性论文,进行严格评估,并根据英国国家卫生与临床优化研究所(NICE)证据水平标准化等级对定量论文进行评分。
通过自我报告或生化分析评估成功戒烟者的百分比和戒烟时长。在定性研究中,必须探究已确定的戒烟障碍。
最终选择了3篇定性论文和13篇定量论文。确定了有效的干预措施和戒烟障碍。安非他酮联合咨询的药物支持在实现长期戒烟方面比安慰剂显著更有效,成功率高18.9%(95%置信区间3.6 - 26.4%)。对于COPD吸烟患者,每年进行一次肺功能测定并进行简短的戒烟干预,随后收到医生的亲笔信,与肺功能正常的吸烟者相比,三年时≥1年的戒烟率显著更高(P < 0.001;z = 3.93)。已确定的戒烟障碍包括:患者信息错误、动机水平、健康观念以及与医疗专业人员沟通不畅。
尽管COPD具有公共卫生意义,但缺乏高质量证据表明哪些戒烟支持方法对这些患者有效。本综述描述了三种有效的干预措施以及戒烟成功的预测因素,服务提供者可利用这些因素提高该群体的戒烟率。还确定了迫切需要进一步研究的领域。